C WorldWide Group’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

C WorldWide Group’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-92,498	Closed	-$13.5M	–	93
2022 Q2	$13.5M	Sell	92,498 -80,000	-46%	-$10.2M	0.17%	38
2022 Q1	$20.5M	Sell	172,498 -40,000	-19%	-$4.99M	0.22%	33
2021 Q4	$29.3M	Sell	212,498 -20,000	-9%	-$2.54M	0.28%	25
2021 Q3	$32.3M	Sell	232,498 -15,000	-6%	-$1.87M	0.33%	24
2021 Q2	$24M	Hold	247,498	–	–	0.25%	29
2021 Q1	$16.9M	Buy	247,498 +60,000	+32%	+$4.85M	0.17%	44
2020 Q4	$16.1M	Sell	187,498 -64,253	-26%	-$5.44M	0.16%	47
2020 Q3	$16.4M	Buy	251,751 +50,000	+25%	+$3.28M	0.18%	43
2020 Q2	$14.8M	Sell	201,751 -110,000	-35%	-$5.85M	0.17%	43
2020 Q1	$10.6M	Hold	311,751	–	–	0.15%	44
2019 Q4	$17M	Hold	311,751	–	–	0.2%	35
2019 Q3	$13M	Hold	311,751	–	–	0.16%	36
2019 Q2	$13.7M	Sell	311,751 -70,000	-18%	-$3.95M	0.17%	42
2019 Q1	$19.6M	Buy	381,751 +83,001	+28%	+$3.59M	0.25%	27
2018 Q4	$11M	Buy	+298,750	New	+$10.8M	0.16%	36

Other funds holding BHVN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SFM

Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

C WorldWide Group's BHVN Position: Q3 2022 in Review

C WorldWide Group sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q3 2022, closing a stake of 92,498 shares — an estimated $13.5M sold.

C WorldWide Group first reported a position in BHVN in Q4 2018 and held it in 15 quarters. The position peaked at $32.3M in Q3 2021. 240 funds tracked by Wall St. Rank hold BHVN as of Q3 2022.

C WorldWide Group reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q3 2022 after selling out during the quarter.
C WorldWide Group sold 92,498 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2022, an estimated $13.5M.
C WorldWide Group first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2018 and held it in 15 quarters.
C WorldWide Group's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $32.3M in Q3 2021.
240 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2022.

Based on C WorldWide Group's 13F filing for Q3 2022, filed 3 Nov 2022.